Literature DB >> 20884714

Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study.

Takaaki Ono, Akihiro Takeshita, Masako Iwanaga, Norio Asou, Tomoki Naoe, Ryuzo Ohno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20884714      PMCID： PMC3012784          DOI： 10.3324/haematol.2010.030205

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.

Authors:  Norio Asou; Yuji Kishimoto; Hitoshi Kiyoi; Masaya Okada; Yasukazu Kawai; Motohiro Tsuzuki; Kentaro Horikawa; Mitsuhiro Matsuda; Katsuji Shinagawa; Tohru Kobayashi; Shigeki Ohtake; Miki Nishimura; Masatomo Takahashi; Fumiharu Yagasaki; Akihiro Takeshita; Yukihiko Kimura; Masako Iwanaga; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

2.  Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.

Authors:  C Callens; S Chevret; J-M Cayuela; B Cassinat; E Raffoux; S de Botton; X Thomas; A Guerci; N Fegueux; A Pigneux; A-M Stoppa; T Lamy; F Rigal-Huguet; A Vekhoff; S Meyer-Monard; A Ferrand; M Sanz; C Chomienne; P Fenaux; H Dombret
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

3.  High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.

Authors:  R F Schlenk; U Germing; F Hartmann; A Glasmacher; J T Fischer; F del Valle y Fuentes; K Götze; H Pralle; C Nerl; H Salwender; W Grimminger; A Petzer; M Hensel; A Benner; L Zick; K Döhner; S Fröhling; H Döhner
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

4.  Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.

Authors:  J M Hernández; G Martín; N C Gutiérrez; J Cervera; M T Ferro; M J Calasanz; J A Martínez-Climent; E Luño; M Tormo; C Rayón; J Díaz-Mediavilla; M González; J D González-San Miguel; K Pérez-Equiza; C Rivas; J Esteve; M del C Alvarez; J Odriozola; J M Ribera; M A Sanz
Journal:  Haematologica       Date:  2001-08       Impact factor: 9.941

5.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

Authors:  S De Botton ; S Chevret; M Sanz; H Dombret; X Thomas; A Guerci; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P Cony Makhoul ; P Travade; E Solary; N Fegueux; D Bordessoule; J San Miguel ; H Link; B Desablens; A Stamatoullas; E Deconinck; K Geiser; U Hess; F Maloisel; S Castaigne; C Preudhomme; C Chomienne; L Degos; P Fenaux
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 6.  Treatment of acute promyelocytic leukemia.

Authors:  Miguel A Sanz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

7.  Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Authors:  Rosemary E Gale; Robert Hills; Arnold R Pizzey; Panagiotis D Kottaridis; David Swirsky; Amanda F Gilkes; Elizabeth Nugent; Kenneth I Mills; Keith Wheatley; Ellen Solomon; Alan K Burnett; David C Linch; David Grimwade
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Authors:  José Cervera; Pau Montesinos; Jesús M Hernández-Rivas; María J Calasanz; Anna Aventín; María T Ferro; Elisa Luño; Javier Sánchez; Edo Vellenga; Chelo Rayón; Gustavo Milone; Javier de la Serna; Concha Rivas; José D González; Mar Tormo; Elena Amutio; Marcos González; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

9.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

10.  Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.

Authors:  C Schoch; D Haase; T Haferlach; M Freund; H Link; E Lengfelder; H Löffler; T Büchner; C Fonatsch
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998
View more
  5 in total

1.  [Clinical and genetic characteristics of patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective of 790 cases].

Authors:  M Z Yang; L Li; H Wei; B C Liu; K Q Liu; D P Li; L Zhang; R C Yang; Y C Mi; J X Wang; Y Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

2.  miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer.

Authors:  Yun Zhu; Cindy Wang; Scott A Becker; Katie Hurst; Lourdes M Nogueira; Victoria J Findlay; E Ramsay Camp
Journal:  Mol Ther       Date:  2018-01-04       Impact factor: 11.454

3.  Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era.

Authors:  Maria Pagoni; Maria Garofalaki; Fotios Panitsas; Kalliopi Manola; Katerina Psarra; Panagiotis Economopoulos; Aggeliki Vourtsi; Marios Antoniades; Kostas Gkirkas; Evangelia Tzouvara; Fotis Katis; Chrystalla Prokopiou; Irene Tziotziou; Artemis Balta; Eleni Lemissiou; Panagiotis Tsirigotis; Panagiotis Repoussis; Nicolas Harhalakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

4.  Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.

Authors:  Zachary D Epstein-Peterson; Andriy Derkach; Susan Geyer; Krzysztof Mrózek; Jessica Kohlschmidt; Jae H Park; Sridevi Rajeeve; Eytan M Stein; Yanming Zhang; Harry Iland; Lynda J Campbell; Richard A Larson; Xavier Poiré; Bayard L Powell; Wendy Stock; Richard M Stone; Martin S Tallman
Journal:  Blood Adv       Date:  2022-06-14

5.  Molecular characteristics and chromatin texture features in acute promyelocytic leukemia.

Authors:  Mariana R B De Mello; Dulcineia M Albuquerque; Fernanda Gonçalves Pereira-Cunha; Krizzia B Albanez; Katia B B Pagnano; Fernando F Costa; Konradin Metze; Irene Lorand-Metze
Journal:  Diagn Pathol       Date:  2012-06-28       Impact factor: 2.644
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.